Skip to main content

Dr. Benjamin A. Weinberg, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
15
In the NPI registry since
2011
Medicare patients seen, 2024
145

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2011Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    DC license MD040203
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
145
Services billed
498
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes16965
Established patient office or other outpatient visit, 40-54 minutes13738
Established patient office or other outpatient visit, 20-29 minutes4934
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes2514
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2323
New patient office or other outpatient visit, 60-74 minutes2020

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 77 payments worth $66,778 in total to this clinician.

By company
Jazz Pharmaceuticals Inc.$38,982
Pfizer Inc.$11,037
Partner Therapeutics, Inc.$7,047
Sirtex Medical Inc$6,491
Array Biopharma Inc$1,966
Caris Mpi, Inc.$450
Lilly USA, LLC$425
Exelixis Inc.$307
By type
Compensation for services other than consulting (speaking, faculty)$36,490
Consulting Fee$21,175
Travel and Lodging$7,243
Food and Beverage$1,870

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 5, 2025Jazz Pharmaceuticals Inc.
Sep 5, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$8,850
Jan 21, 2025Jazz Pharmaceuticals Inc.
Jan 21, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
May 7, 2025Jazz Pharmaceuticals Inc.
May 7, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jul 23, 2025Jazz Pharmaceuticals Inc.
Jul 23, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Mar 13, 2025Partner Therapeutics, Inc.
Mar 13, 2025
Consulting Fee
Bizengri · Hematology/Oncology
$5,625
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)
SIR-Spheres Microspheres · Interventional Oncology
$5,500
May 5, 2025Jazz Pharmaceuticals Inc.
May 5, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$5,310
Mar 14, 2025Pfizer Inc.
Mar 14, 2025
Consulting Fee
XELJANZ · GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT
$5,125
May 19, 2025Pfizer Inc.
May 19, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$4,250
Apr 30, 2025Jazz Pharmaceuticals Inc.
Apr 30, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind
$852
All 47 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Sep 5, 2025Jazz Pharmaceuticals Inc.
Sep 5, 2025
Consulting Fee
ZIIHERA · HEMATOLOGY/ONCOLOGY
$8,850
Jul 23, 2025Jazz Pharmaceuticals Inc.
Jul 23, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jul 10, 2025Caris Mpi, Inc.
Jul 10, 2025
Consulting Fee
MI CANCER SEEK · ONCOLOGY
$300
Jun 12, 2025Caris Mpi, Inc.
Jun 12, 2025
Consulting Fee
MI CANCER SEEK · ONCOLOGY
$150
May 31, 2025Pfizer Inc.
May 31, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind
$505
May 29, 2025Pfizer Inc.
May 29, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind
$213
May 21, 2025Pfizer Inc.
May 21, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind
$104
May 19, 2025Pfizer Inc.
May 19, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$4,250
May 12, 2025Jazz Pharmaceuticals Inc.
May 12, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind
$57.86
May 7, 2025Jazz Pharmaceuticals Inc.
May 7, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
May 5, 2025Jazz Pharmaceuticals Inc.
May 5, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$5,310
Apr 30, 2025Jazz Pharmaceuticals Inc.
Apr 30, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind
$852
Apr 30, 2025Jazz Pharmaceuticals Inc.
Apr 30, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Baltimore, MD · in-kind
$70.00
Apr 30, 2025Jazz Pharmaceuticals Inc.
Apr 30, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Baltimore, MD · in-kind
$16.65
Apr 26, 2025Sirtex Medical Inc
Apr 26, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to CLEVELAND, OH
$126
Apr 24, 2025Jazz Pharmaceuticals Inc.
Apr 24, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind
$338
Apr 16, 2025Jazz Pharmaceuticals Inc.
Apr 16, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind
$138
Apr 16, 2025Jazz Pharmaceuticals Inc.
Apr 16, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind
$127
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Compensation for services other than consulting (speaking, faculty)
SIR-Spheres Microspheres · Interventional Oncology
$5,500
Apr 11, 2025Pfizer Inc.
Apr 11, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind
$649
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to DULLES, VA
$74.26
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to DULLES, VA
$47.89
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to WESTLAKE, OH
$33.91
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to WESTLAKE, OH
$31.93
Apr 11, 2025Sirtex Medical Inc
Apr 11, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to WESTLAKE, OH
$14.91
Apr 9, 2025Array Biopharma Inc
Apr 9, 2025
Compensation for services other than consulting (speaking, faculty)
BRAFTOVI · ONCOLOGY
$190
Mar 27, 2025Sirtex Medical Inc
Mar 27, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to CLEVELAND, OH
$484
Mar 27, 2025Sirtex Medical Inc
Mar 27, 2025
Travel and Lodging
SIR-Spheres Microspheres · Interventional Oncology · travel to CLEVELAND, OH
$37.50
Mar 26, 2025Jazz Pharmaceuticals Inc.
Mar 26, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind
$225
Mar 19, 2025Jazz Pharmaceuticals Inc.
Mar 19, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Smithfield, RI · in-kind
$121
Mar 14, 2025Pfizer Inc.
Mar 14, 2025
Consulting Fee
XELJANZ · GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT
$5,125
Mar 13, 2025Partner Therapeutics, Inc.
Mar 13, 2025
Consulting Fee
Bizengri · Hematology/Oncology
$5,625
Mar 13, 2025Partner Therapeutics, Inc.
Mar 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$62.21
Mar 13, 2025Partner Therapeutics, Inc.
Mar 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$52.98
Mar 13, 2025Partner Therapeutics, Inc.
Mar 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$45.90
Mar 2, 2025Array Biopharma Inc
Mar 2, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Orlando, FL · in-kind
$465
Mar 2, 2025Array Biopharma Inc
Mar 2, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Orlando, FL · in-kind
$337
Mar 2, 2025Array Biopharma Inc
Mar 2, 2025
Travel and Lodging
BRAFTOVI · ONCOLOGY · travel to Orlando, FL · in-kind
$275
Feb 28, 2025Array Biopharma Inc
Feb 28, 2025
Consulting Fee
BRAFTOVI · ONCOLOGY
$700
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind
$467
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$454
Jan 28, 2025Jazz Pharmaceuticals Inc.
Jan 28, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind
$177
Jan 27, 2025Jazz Pharmaceuticals Inc.
Jan 27, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Smithfield, RI · in-kind
$218
Jan 21, 2025Jazz Pharmaceuticals Inc.
Jan 21, 2025
Compensation for services other than consulting (speaking, faculty)
ZIIHERA · HEMATOLOGY/ONCOLOGY
$7,080
Jan 15, 2025Lilly USA, LLC
Jan 15, 2025
Consulting Fee
CYRAMZA · Oncology
$425
Jan 10, 2025Jazz Pharmaceuticals Inc.
Jan 10, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind
$214
Jan 10, 2025Jazz Pharmaceuticals Inc.
Jan 10, 2025
Travel and Lodging
ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind
$208

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in District of Columbia →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 9 companies. The companies reported $1,602,389 in research payments for these studies, mostly to the institutions running them.

  • NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
    Ipsen Biopharmaceuticals, Inc · Active, not recruiting · NCT04005339
  • STUDY NAME#Phase II Trial of BXCL701 and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma
    Merck Sharp & Dohme LLC
  • Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors
    Exelixis Inc.
  • A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
    Janssen Research & Development, LLC
  • A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
    AstraZeneca Pharmaceuticals LP
  • An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
    Pfizer Inc.
  • A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
    Incyte Corporation
  • A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer
    Janssen Research & Development, LLC
  • A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
    AstraZeneca UK Limited
  • A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously…
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Washington

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 7, 2017), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1598064941. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.